Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib for Amyotrophic Lateral Sclerosis
ChiCTR2400092197Phase 2Not yet recruiting
- Sponsor
- The First College of Clinical Medical Science, China Three Gorges University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in amyotrophic lateral sclerosis (ALS), sponsored by The First College of Clinical Medical Science, China Three Gorges University. Primary endpoints: Serum RIPK1 and Serum IL-8. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
crizotinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2400092197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092197.